Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group LimitedfiledCriticalGlaxo Group Limited
Priority claimed from PCT/EP2002/012482external-prioritypatent/WO2003041722A1/en
Publication of HK1070561A1publicationCriticalpatent/HK1070561A1/en
Publication of HK1070561BpublicationCriticalpatent/HK1070561B/en
Verwendung einer 2,5 mg-Dosis des Pentasaccharids Methyl-O-(2-desoxy-2-sulfoamino-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(β-D-glucopyranosyluronsäure)-(1→4)-O-(2-desoxy-2-sulfoamino-3,6-di-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(2-O-sulfo-α-L-idopyranosyluronsäure)-(1→4)-2-desoxy-2-sulfoamino-6-O-sulfo-α-D-glucopyranosid oder eines pharmazeutisch verträglichen Salzes davon für die Herstellung eines Arzneimittels zur Behandlung des akuten Koronarsyndroms (ACS).
Verwendung nach Anspruch 1, wobei das Pentasaccharid in Form seines Decanatriumsalzes vorliegt.
Verwendung nach Anspruch 1 oder 2 zur Behandlung von Nicht-ST-Hebungs-ACS.
HK05101101.9A2001-11-132002-11-07Use of specific dose of fondaparinux sodium for the treatment of acs
HK1070561B
(en)
Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial.
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate
Anvendelse af AICA-ribosid eller AICA-ribotid til fremstilling af et farmaceutisk præparat til behandling af hjerteanfald eller salgtilfælde i patienter, som lider af atherosklerose
HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte
Dawka pentasacharydu metylo-O-(2,3,4-tri-O-metylo-6-O-sulfo-α-D-glukopiranozylo)-(1→4)-O-(2,3-di-O-metylo-β-D-glukopiranozylo kwas uronowy)-(1→4)-O-(2,3,6-tri-O-sulfo-α-D-glukopiranozylo)-(1→4)-O-(2,3-di-O-metylo-α-L-idopiranozylo kwas uronowy)-(1→4)-2,3,6-tri-O-sulfo-α-D-glukopiranozydu i jej zastosowanie
An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction